Deuterium Depleted Water as an Adjuvant in Treatment of Cancer

Systematic Reviews in Pharmacy,2019,10,1s,s26-s31.
Published:August 2019
Type:Review Article

Deuterium Depleted Water as an Adjuvant in Treatment of Cancer

Anton Syroeshkin*, Olga Levitskaya*, Elena Uspenskaya, Tatiana Pleteneva, Maria Makarova, Daria Romaykina, Daria Ermakova

Department of Pharmaceutical and Toxicological Chemistry, Medical Institute, Peoples' Friendship University of Russia, 6 Miklukho-Maklaya Street, Moscow, 117198, RUSSIAN FEDERATION.


For more than 20 years, since 1993, the Hungarian National Institute of Pharmacy and Nutrition has been conducting a research on the mechanisms of antitumor activity of light water (deuterium depleted water – DDW). Long-term randomized clinical trials in numerous treatment centers in Hungary in compliance with the Good Clinical Practice (GCP) indicate a high sensitivity of tumor cells to lower levels of deuterium (D) in the body. The replacement of the ordinary water (D)/H = 140 ppm) by the “light” one (D/H = 20-105 ppm) is accompanied by a decrease in the size of the tumor, gradual necrosis of tumor cells, an increase in the median survival of cancer patients (prostate cancer, breast cancer, lung cancer, etc.). The content of deuterium in the body at the level of 10-12 mmol is an order of magnitude higher compared to essential trace elements, which makes it possible to predict its key role in biochemical processes. Indeed, mass-spectrometric analysis shows that deuterium bioaccumulation in the human body depends on its phenotype. In contrast, when drinking water is replaced with DDW, the deuterium content in aqueous extracts of biological blood samples, muscle and liver tissues of laboratory animals goes down. The use of DDW as a prophylactic agent and many experimental results obtained in vitro and in vivo in China, Japan, the USA, Romania, and the Russian Federation make it possible to recommend DDW for use as a safe additional agent in the treatment of cancer.